American Journal of Ophthalmology
Volume 145, Issue 1 , Pages 114-119 , January 2008

Prostaglandins Increase Trabecular Meshwork Outflow Facility in Cultured Human Anterior Segments

,Accepted 1 September 2007.

References 

  1. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38:2772–2780
  2. Weinreb RN, Lindsey JD, Marchenko G, Marchenko N, Angert M, Strongin A. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci. 2004;45:4368–4377
  3. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63
  4. Parrish RK, Palmberg P, Sheu WP XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688–703
  5. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004;111:1658–1662
  6. Lim KS, Nau CB, O’Byrne MM, et al. The mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects: a crossover study. Ophthalmology. 2007;Forthcoming.
  7. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F-2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351–1358
  8. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, VanDenburgh AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131:19–24
  9. Fatt I, Hedbys BO. Flow of water through the sclera. Exp Eye Res. 1970;10:243–249
  10. Jackson TL, Hussain A, Hodgetts A, et al. Human scleral hydraulic conductivity: Age-related changes, topographical variation, and potential scleral outflow facility. Invest Ophthalmol Vis Sci. 2006;47:4942–4946
  11. Kim JW, Lindsey JD, Wang N, Weinreb RN. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci. 2001;42:1514–1521
  12. Johnson DH, Tschumper RC. Human trabecular meshwork organ culture: a new method. Invest Ophthalmol Vis Sci. 1987;28:945–953
  13. Johnson DH, Tschumper RC. The effect of organ culture on human trabecular meshwork. Exp Eye Res. 1989;49:113–127
  14. Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47:S6–S12
  15. Johnson DH. The effect of cytochalasin D on outflow facility and the trabecular meshwork of the human eye in perfusion organ culture. Invest Ophthalmol Vis Sci. 1997;38:2790–2799
  16. Bulin C, Bode AJG, Weber AA, Schror K, Levkau B, Fischer JW. Differential effects of vasodilatory prostaglandins on focal adhesions, cytoskeletal architecture, and migration in human aortic smooth muscle cells. Arteriosclerosis Thromb Vasc Biol. 2005;25:84–89
  17. Linden C, Alm A. Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes. Arch Ophthalmol. 1997;115:857–861
  18. Lee P, Shao H, Xu L, Qu C. The effect of prostaglandin F-2α on intraocular pressure in normotensive human subjects. Invest Ophthalmol Vis Sci. 1988;29:1474–1477
  19. Villumsen J, Alm A. Prostaglandin F-2α-isopropylester eye drops: Effects in normal human eyes. Br J Ophthalmol. 1989;73:419–426
  20. Nilsson SFE, Drecoll E, Lutjen-Drecoll E, et al. The prostandoid EP2-receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 2006;47:4042–4049
  21. Dijkstra BG, Schneemann A, Hoyng PF. Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999;40:2622–2626
  22. Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:3887–3895
  23. Thieme H, Schimmat C, Munzer G, et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F-2α and fluporstenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006;47:938–945
  24. Bahler CK, Hann CR, Fautsch MP, Johnson DH. Pharmacologic disruption of Schlemm’s canal cells and outflow facility in anterior segments of human eyes. Invest Ophthalmol Vis Sci. 2004;45:2246–2254
  25. Richter M, Krauss AH, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44:4419–4426
  26. Kim JW, Lindsey JD, Wang N, Weinreb RN. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci. 2001;42:1514–1521
  27. Lindsey JD, Crowston JG, Tran A, Morris C, Weinreb RN. Direct matrix metalloproteinase enhancement of transscleral permeability. Invest Ophthalmol Vis Sci. 2007;48:752–755

PII: S0002-9394(07)00779-9

doi: 10.1016/j.ajo.2007.09.001

American Journal of Ophthalmology
Volume 145, Issue 1 , Pages 114-119 , January 2008

Article Tools

* Image Usage & Resolution